Arbutus to Participate in Upcoming Investor Conferences
06 mars 2017 06h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 06, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
Arbutus to Participate in Upcoming Investor Conferences
09 févr. 2017 16h30 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
Arbutus Is Granted a Pre-trial Injunction Restraining Acuitas From Entering Into Agreements Sublicensing Arbutus LNP Technology
08 févr. 2017 06h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on...
Arbutus Provides Additional Data from the ARB-1467 Phase II Clinical Trial in HBV Patients
12 déc. 2016 16h00 HE
|
Arbutus Biopharma Corporation
Complete Cohort 1 and 2 ARB-1467 Multi-Dose Data Demonstrate Dose-Responsive HBsAg ReductionsGreater Than 1.0 log10 Reduction in Serum HBsAg Observed in 3/5 Patients After Receiving Three Monthly...
Arbutus Presents HBV Drug Combination Studies at AASLD
14 nov. 2016 16h01 HE
|
Arbutus Biopharma Corporation
Combinations of Arbutus RNAi and Capsid Assets and Approved Drugs Show Complementary ActionCapsid Inhibitor AB-423 Has Dual Mode of Action; Inhibits HBV DNA and cccDNA SynthesisSecond Generation...
Arbutus Provides Corporate Update and Announces Third Quarter 2016 Financial Results
03 nov. 2016 16h30 HE
|
Arbutus Biopharma Corporation
Additional ARB-1467 Multi-Dose Data in 4Q16Cash Runway into Late 2018 VANCOUVER, B.C. and DOYLESTOWN, Pa., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an...
Arbutus Recognizes Liver Cancer Awareness Month with Grant to Support the Hepatitis B Foundation’s Patient Storytelling Campaign
03 oct. 2016 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Oct. 03, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
Arbutus to Present HBV Data at the 2016 AASLD Liver Meeting
01 oct. 2016 12h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Oct. 01, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions...
Arbutus Reports Interim Multi-Dose Results from Phase II Clinical Trial of ARB-1467 in Patients with Chronic HBV Infection
29 sept. 2016 16h01 HE
|
Arbutus Biopharma Corporation
Single Dose Data Demonstrate Significant Reduction in Serum HBsAgAdditive Reductions in Serum HBsAg Observed with Repeat Dosing over 3 Months5 of 6 Patients in Cohort 1 Had Serum HBsAg Reductions...
Arbutus’ Chief Scientific Officer, Dr. Michael J. Sofia, Awarded the 2016 Lasker~DeBakey Clinical Medical Research Award
13 sept. 2016 07h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...